Exelgyn is a French pharmaceutical company which makes and distributes the medical abortion drugs mifepristone (marketed as Mifegyne) and misoprostol.
| Industry | Pharmaceutical |
|---|---|
| Headquarters | Paris, France |
Area served | Worldwide |
| Products | mifepristone, misoprostol. |
| Website | https://exelgyn.com/ |
History
editMifepristone was originally developed by the French pharmaceutical company Roussel-Uclaf. In 1997, after buying the remaining 43.5% of Roussel-Uclaf stock in early 1997,[1] Hoechst AG announced the end of its manufacture and sale of Mifegyne and the transfer of all rights for medical uses of mifepristone outside of the United States to Exelgyn S.A., a new single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz.[2]
In 1999, Exelgyn won approval of Mifegyne in 11 additional countries.[3] As of 2024, Exelgyn distributes mifepristone to 40 countries,[4] but within the United States it is distributed by Danco Laboratories.
References
edit- ^ Moore SD, Kamm T, Fleming C (11 December 1996). "Hoechst to seek rest of Roussel-Uclaf; expected $3.04 billion offer would add to the wave of drug-sector linkups". The Wall Street Journal. p. A3.
Marshall M (11 December 1996). "Hoechst offers to pay $3.6 billion for rest of Roussel". The Wall Street Journal. p. A8.
"Hoechst to buy rest of Roussel". The New York Times. Bloomberg News. 11 December 1996. p. D4. Archived from the original on 25 June 2016. - ^ "Pill for abortion ends production". The New York Times. Bloomberg News. 9 April 1997. p. D2. Archived from the original on 25 June 2016.
Jouzaitis C (9 April 1997). "Abortion pill maker bows to boycott heat; German firm gives up RU-486 patent; little impact likely in U.S." Chicago Tribune. p. 4. Archived from the original on 18 February 2013.
Lavin D (9 April 1997). "Hoechst will stop making abortion pill". The Wall Street Journal. p. A3.
"Roussel-Uclaf to transfer RU 486 rights". Reprod Freedom News. 6 (7): 8. 18 April 1997. PMID 12292550.
Dorozynski A (19 April 1997). "Boycott threat forces French company to abandon RU486". BMJ. 314 (7088): 1150. doi:10.1136/bmj.314.7088.1145m. PMC 2126515. PMID 9146386. - ^ "List of mifepristone approval" (PDF). New York: Gynuity Health Projects. 4 November 2009. Archived from the original (PDF) on 26 July 2011. Retrieved 4 May 2018.
"Map of mifepristone approval" (PDF). New York: Gynuity Health Projects. 4 November 2009. Archived from the original (PDF) on 26 July 2011. Retrieved 11 June 2010. - ^ https://exelgyn.com/our-global-presence/